The development of preventive strategies in early-stage Alzheimer's disease (AD) requires measures that can predict future brain atrophy. Gray matter network measures are related to amyloid burden in cognitively normal older individuals and predict clinical progression in preclinical AD. Here, we show that within individuals with preclinical AD, gray matter network measures predict hippocampal atrophy rates, whereas other AD biomarkers (total gray matter volume, cerebrospinal fluid total tau, and Mini-Mental State Examination) do not. Furthermore, in brain areas where amyloid is known to start aggregating (i.e. anterior cingulate and precuneus), disrupted network measures predict faster atrophy in other distant areas, mostly involving tempo...
Importance β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition ac...
Clinical symptoms observed in Alzheimer's disease (AD) patients may reflect variations within specif...
Background: Changes in grey matter covariance networks have been reported in preclinical and clinica...
The development of preventive strategies in early-stage Alzheimer's disease (AD) requires measures t...
Biomarkers are needed to monitor disease progression in Alzheimer's disease. Grey matter network mea...
We studied whether gray matter network parameters are associated with rate of clinical progression i...
Individuals with prodromal Alzheimer's disease show considerable variability in rates of cognitive d...
Gray matter networks are disrupted in Alzheimer's disease and related to cognitive impairment. Howev...
The accumulation of amyloid plaques is one of the earliest pathological changes in Alzheimer’s disea...
The accumulation of amyloid plaques is one of the earliest pathological changes in Alzheimer's disea...
Structural grey matter covariance networks provide an individual quantification of morphological pat...
Gray matter networks are disrupted in Alzheimer's disease (AD). It is unclear when these disruptions...
A substantial proportion of cognitively healthy elders (HC) show abnormally high amyloid-β (Aβ) depo...
Importance β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition ac...
Clinical symptoms observed in Alzheimer's disease (AD) patients may reflect variations within specif...
Background: Changes in grey matter covariance networks have been reported in preclinical and clinica...
The development of preventive strategies in early-stage Alzheimer's disease (AD) requires measures t...
Biomarkers are needed to monitor disease progression in Alzheimer's disease. Grey matter network mea...
We studied whether gray matter network parameters are associated with rate of clinical progression i...
Individuals with prodromal Alzheimer's disease show considerable variability in rates of cognitive d...
Gray matter networks are disrupted in Alzheimer's disease and related to cognitive impairment. Howev...
The accumulation of amyloid plaques is one of the earliest pathological changes in Alzheimer’s disea...
The accumulation of amyloid plaques is one of the earliest pathological changes in Alzheimer's disea...
Structural grey matter covariance networks provide an individual quantification of morphological pat...
Gray matter networks are disrupted in Alzheimer's disease (AD). It is unclear when these disruptions...
A substantial proportion of cognitively healthy elders (HC) show abnormally high amyloid-β (Aβ) depo...
Importance β-amyloid (Aβ) deposition is one of the hallmarks of Alzheimer disease. Aβ deposition ac...
Clinical symptoms observed in Alzheimer's disease (AD) patients may reflect variations within specif...
Background: Changes in grey matter covariance networks have been reported in preclinical and clinica...